Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide <i>In Vivo</i>

26 Feb 2015

Abstract excerpt

Triple-negative breast cancer (TNBC) has the lowest 5-year survival rate of invasive breast carcinomas, and currently there are no approved targeted therapies for this aggressive form of the disease. The androgen receptor (AR) is expressed in up to one third of TNBC and we find that all AR(+) TNBC primary tumors tested display nuclear localization of AR, indicative of transcriptionally active receptors. While AR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25713333
DOI: 10.1158/1535-7163.mct-14-0926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide <i>In Vivo</i>PMID 25713333Read ↗

[Androgen receptor-positive triple negative breast cancer: From biology to therapy].Semantic proximity Read ↗

Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.Semantic proximity Read ↗

Divide and Conquer—Targeted Therapy for Triple-Negative Breast CancerSemantic proximity Read ↗

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.Semantic proximity Read ↗

Non-canonical AR activity facilitates endocrine resistance in breast cancerSemantic proximity Read ↗

Assessing the Androgen Receptor Status in Clinicopathologic and Hematologic Characteristics of the Triple-negative Breast CancerSemantic proximity Read ↗

Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.Semantic proximity Read ↗

The Small G-Protein RalA Promotes Progression and Metastasis of Triple Negative Breast CancerSemantic proximity Read ↗

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting basal-like breast cancers.Semantic proximity Read ↗

Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex AssemblySemantic proximity Read ↗

Targeted and cytotoxic inhibitors used in the treatment of breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.